The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

This medication is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). Sotatercept helps to improve your ability to exercise and to slow down worsening of PAH. Read ...

A recently approved injectable significantly stalls health deterioration in patients with pulmonary hypertension Sotatercept reduced risk of deterioration by 76% Patients were better able to keep ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved sotatercept (Winrevair, Merck Sharp & Dohme) as a new treatment to improve exercise capacity in patients with pulmonary ...

The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday. A novel activin signaling inhibitor, sotatercept is indicated to ...

(CNN) — When doctors told Katrina Barry that she had a rare and serious condition called pulmonary arterial hypertension or PAH, they warned her not to Google it. Come on, she thought; they wanted a ...

The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial hypertension (PAH). “Pulmonary arterial hypertension is a devastating disease for ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk ...